Navigation Links
Johns Hopkins receives funding for cholera vaccine initiative
Date:12/27/2012

The Johns Hopkins Bloomberg School of Public Health was awarded a four-year, $5 million grant from the Bill & Melinda Gates Foundation to promote the effective use of oral cholera vaccine around the world. The Delivering Oral Vaccine Effectively (DOVE) program will provide relief agencies and governments with technical assistance on how to use oral cholera vaccine, evaluate current vaccine-use practices and develop new field surveillance methods for monitoring and controlling outbreaks of the disease.

Cholera is an infectious disease caused by drinking unsanitary water. The disease is estimated to be responsible for between 100,000 to 200,000 deaths worldwide each year and infects as many as 2.5 million people annually. The oral cholera vaccine is over 70 percent effective and costs $1.85 per dose, but is not yet widely used in preventing outbreaks.

"We believe this grant will greatly facilitate the appropriate use of the new cholera vaccine. In partnership with the World Health Organization, UNICEF and other national and international agencies, we believe the DOVE project will provide the knowledge, technical assistance and encouragement to bring this life-saving vaccine to those who need it most," said David Sack, MD, director of DOVE and professor in the Department of International Health at the Bloomberg School.

In addition to researching and evaluating vaccine-use practices, DOVE will establish cholera surveillance in the northern region of Cameroon near Lake Chad, which appears to be a cholera hotspot. The site will help researchers develop and study methods for detecting outbreaks in remote areas and potentially for using oral vaccine to contain the disease.

The DOVE program will be part of a network of vaccine projects funded by the Gates Foundation to prevent outbreaks of cholera worldwide.


'/>"/>

Contact: Tim Parsons
tmparson@jhsph.edu
410-955-7619
Johns Hopkins University Bloomberg School of Public Health
Source:Eurekalert

Page: 1

Related medicine news :

1. US Drug Watchdog Now Urges Loved Ones Of A Diabetic Who Died From Bladder Cancer Who Had Used The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
2. A Serious Problem: Medical Malpractice Lawyers at Console & Hollawell React to Alarming Doctor Error Statistics from Johns Hopkins University Researchers
3. US Drug Watchdog Now Fears Most Women Never Heard About Yaz or Yasmin Birth Control Pill Side Effects and They Urge to Victims to Call the Johnson Law Group-Get Help Now
4. US Drug Watchdog Now Urges Any US Citizen Who Used the Diabetes Drug Called Actos and Then Developed Bladder Cancer To Contact The Johnson Law Group For A Legal Review
5. Johns Hopkins malpractice study: Surgical never events occur at least 4,000 times per year
6. US Drug Watchdog Now Urges Yaz Yasmin Birth Control Pill Users Who Suffered a Stroke, Blood Clots, or a Heart Attack to Call the Johnson Law Group for a Legal Review
7. US Drug Watchdog Now Urges Users Of The Diabetes Drug Called Actos To Call The Johnson Law Group if They Have Developed Bladder Cancer-Time Is Of The Essence
8. Johns Hopkins to aid The Leapfrog Group in grading the safety and quality of US hospitals
9. US Drug Watchdog Now Urges Family Members Of A Diabetic Who Died From Bladder Cancer After Using The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
10. US Drug Watchdog Now Urges Yaz Yasmin Birth Control Pill Users Who Suffered a Pulmonary Embolism or a Heart Attack to Call the Johnson Law Group Now-Before Time Runs Out
11. Fasting may benefit patients with epilepsy, Johns Hopkins Childrens Center study suggests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: